United Laboratories International Holdings (FRA:UNJ) EBIT : €439 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is United Laboratories International Holdings EBIT?

United Laboratories International Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was €226 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €439 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. United Laboratories International Holdings's annualized ROC % for the quarter that ended in Dec. 2023 was 27.52%. United Laboratories International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 52.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. United Laboratories International Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 23.51%.

United Laboratories International Holdings EBIT Historical Data

The historical data trend for United Laboratories International Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Laboratories International Holdings EBIT Chart

United Laboratories International Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

144.04

133.70

175.47

282.77

438.07

United Laboratories International Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															70.63	119.93	167.85	212.78	226.05

Competitive Comparison of United Laboratories International Holdings's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Laboratories International Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's EV-to-EBIT falls into.

United Laboratories International Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €439 Mil.

United Laboratories International Holdings (FRA:UNJ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

United Laboratories International Holdings's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	445.108 * ( 1 - 18.21% )	/	( (1213.384	+	1431.909)	/ 2 )
=	364.0538332	/	1322.6465
=	27.52 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2548.059	-	720.32	-	( 614.355	-	max(0, 910.412	-	1702.845	+	614.355	))
=	1213.384

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2699.19	-	719.923	-	( 547.358	-	max(0, 851.056	-	1770.66	+	547.358	))
=	1431.909

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

United Laboratories International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	452.106	/	( ( (820.676 + max(-124.847, 0))	+	(899.558 + max(-90.927, 0)) )	/	2 )
=	452.106	/	( ( 820.676	+	899.558 )	/	2 )
=	452.106	/	860.117
=	52.56 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(318.164	+	282.47	+	101.905)	-	(720.32	+	0	+	107.066)
=	-124.847

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(303.883	+	287.483	+	143.031)	-	(719.923	+	0	+	105.401)
=	-90.927

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

United Laboratories International Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	438.829	/	1866.289
	=	23.51 %

United Laboratories International Holdings EBIT Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

United Laboratories International Holdings (FRA:UNJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (FRA:UNJ) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

ULIHF:USA 03933:Hong Kong UNJ:Germany

Address

No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG

Website

http://www.tul.com.cn

United Laboratories International Holdings Ltd is a major drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Most of the company's sales are generated in China, followed by Europe and India.

United Laboratories International Holdings (FRA:UNJ) Headlines

No Headlines